Physician profile
Misagh Karimi
NPI 1770583197
$782,308.92
in general payments reported to CMS, 2019-2025
53 companies · $127K in 2025
The $127K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163K · 2020: $47K · 2021: $111K · 2022: $85K · 2023: $104K · 2024: $145K · 2025: $127K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $202K · Consulting Fee: $100K · Travel and Lodging: $52K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Food and Beverage: $5,734 · Honoraria: $1,620 · Grant: $350 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $202,454.25 |
| Consulting Fee | $99,552.50 |
| Travel and Lodging | $51,975.24 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,735.00 |
| Food and Beverage | $5,733.80 |
| Honoraria | $1,620.00 |
| Grant | $350.00 |
| Education | $141.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $177,416.20 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $101,369.26 | 2019-2025 | Keytruda |
| Genentech USA, INC. | $69,737.96 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $62,624.70 | 2019-2025 | Lynparza, Imfinzi, Tagrisso |
| Amgen INC. | $59,811.72 | 2019-2025 | Lumakras |
| Emd Serono, INC. | $55,684.26 | 2023-2025 | |
| Pfizer INC. | $46,872.94 | 2019-2025 | |
| Eisai INC. | $44,356.93 | 2020-2025 | |
| Puma Biotechnology, INC. | $36,891.12 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29,873.76 | 2019-2025 | Fruzaqla |
| Rigel Pharmaceuticals, INC. | $23,131.88 | 2019-2022 | |
| Array Biopharma INC | $15,526.32 | 2019-2025 | Braftovi |
| Exelixis INC. | $12,087.40 | 2019-2025 | Cabometyx |
| Verastem, INC. | $10,384.99 | 2019-2020 | |
| Seagen INC. | $9,999.06 | 2020-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misagh Karimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.